Compare Enveric Biosciences Inc (ENVB) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Tapestry, Inc. — how do they compare? Enveric Biosciences Inc trades at $1.4 (market cap $5.32M), while Tapestry, Inc. trades at $143.85 (market cap $28.34B). The key difference: Tapestry, Inc. is far larger — about 5327.1× Enveric Biosciences Inc's market cap, and Tapestry, Inc. pays a 1.14% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | TPR | |
|---|---|---|
Market Cap | $5.32M | $28.34B |
Sector | Health | Consumer Cyclical |
52-Week High | $17.40 | $160.49 |
52-Week Low | $1.28 | $95.69 |
Enterprise Value | $408.82K | $31.19B |
Dividend Yield | — | 1.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
TPR stock trades at $143.67, up 6.14% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported revenue of $7.01B in 2025 with net income of $183.20M, though margins compressed from prior years. Recent quarters show consistent earnings beats, and analyst sentiment remains strongly positive with a consensus price target of $184.14. Cash flow trends indicate volatility, with 2025 net cash flow negative $5.02B due to financing activities.
Outlook: Strong buy ratings and earnings momentum support upside potential, but elevated valuation ratios and technical bearishness pose near-term risks. Key opportunities include digital growth and brand strength, while risks involve margin pressure and high debt levels. Investors should weigh robust analyst confidence against fundamental headwinds for balanced positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
